Abstract
Though there has been an array of methods to evaluate the extent of sarcoidosis, it is generally difficult to detect central nervous system involvement. Recently it has become accepted that 18F-FDG PET is more sensitive than gallium scintigraphy in finding sarcoid lesions, however its usefulness and limitations for detecting sarcoidosis in the central nervous system, especially in the spinal cord, has rarely been investigated. Two patients with pathologically confirmed sarcoidosis manifested spinal symptoms. We conducted 18F-FDG PET along with conventional imagings before and after treatment. Abnormal FDG uptakes which could not be detected by gallium scintigraphy were shown in the spinal cords in both patients. These abnormal uptakes were diminished in accordance with clinical improvement after treatment. Our findings suggest that 18F-FDG PET is effective in detecting and tracking the activity of spinal sarcoidosis.
Abbreviations
- 18F-FDG:
-
18F-Fluorodeoxyglucose
- PET:
-
Positron emission tomography
- CNS:
-
Central nervous system
- MRI:
-
Magnetic resonance imaging
- CSF:
-
Cerebrospinal fluid
- MS:
-
Multiple sclerosis
- BBB:
-
Blood brain barrier
References
Hoitsma E, Faber CG, Drent M, Sharma OP (2004) Neurosarcoidosis: a clinical dilemma. Lancet Neurol 3:397–407
Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, Scadding JW, Thompson EJ, Chamoun V, Miller DH, McDonald WI, Mitchell D (1999) Central nervous system sarcoidosis-diagnosis and management. QJM 92:103–117
Saleh S, Saw C, Marzouk K, Sharma O (2006) Sarcoidosis of the spinal cord: literature review and report of eight cases. J Natl Med Assoc 98:965–976
Sulavik SB, Spencer RP, Weed DA, Shapiro HR, Shiue ST, Castriotta RJ (1990) Recognition of distinctive patterns of gallium-67 distribution in sarcoidosis. J Nucl Med 31:1909–1914
Larson SM, Milder MS, Johnston GS (1972) Interpretation of the 67 Ga photoscan. J Nucl Med 14:208–214
Pickuth D, Heywang-Köbrunner SH (2000) Neurosarcoidosis: evaluation with MRI. J Neuroradiol 27:185–188
Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231:305–332
Omuro AM, Leite CC, Mokhtari K, Delattre JY (2006) Pitfalls in the diagnosis of brain tumours. Lancet Neurol 5:937–948
Nishiyama Y, Yamamoto Y, Fukunaga K, Takinami H, Iwado Y, Satoh K, Ohkawa M (2006) Comparative evaluation of 18F-FDG PET and 67 Ga scintigraphy in patients with sarcoidosis. J Nucl Med 47:1571–1576
Xiu Y, Yu JQ, Cheng E, Kumar R, Alavi A, Zhuang H (2005) Sarcoidosis demonstrated by FDG PET imaging with negative findings on gallium scintigraphy. Clin Nucl Med 30:193–195
Aide N, Benayoun M, Kerrou K, Khalil A, Cadranel J, Talbot JN (2007) Impact of [18F]-fluorodeoxyglucose([18F]-FDG) imaging in sarcoidosis: unsuspected neurosarcoidosis discovered by [18F]-FDG PET and early metabolic response to corticosteroid therapy. Br J Radiol 80:e67–e71
Dubey N, Miletich RS, Wasay M, Mechtler LL, Bakshi R (2002) Role of fluorodeoxyglucose positron emission tomography in the diagnosis of neurosarcoidosis. J Neurol Sci 205:77–81
Spencer TS, Campellone JV, Maldonado I, Huang N, Usmani Q, Reginato AJ (2005) Clinical and magnetic resonance imaging manifestations of neurosarcoidosis. Semin Arthritis Rheum 34:649–661
Baron EM, Young WF (2007) Cervical spondylotic myelopathy: a brief review of its pathophysiology, clinical course, and diagnosis. Neurosurgery 60:35–41
Cohen PR, Kurzrock R (2007) Sarcoidosis and malignancy. Clin Dermatol 25:326–333
Acknowledgment
We thank Kathryn Soriano for proofreading our manuscript and providing meaningful advice.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ota, K., Tsunemi, T., Saito, K. et al. 18F-FDG PET successfully detects spinal cord sarcoidosis. J Neurol 256, 1943–1946 (2009). https://doi.org/10.1007/s00415-009-5270-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-009-5270-8